DALLAS, May 24, 2015 /PRNewswire-iReach/ -- The report
"Arrhythmias – Pipeline Review, H1 2015" provides
comprehensive information on the therapeutic development for
Arrhythmias, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type, along with latest
updates, and featured news and press releases. It also reviews key
players involved in the therapeutic development for Arrhythmias and
special features on late-stage and discontinued projects.
Photo - http://photos.prnewswire.com/prnh/20150522/218065
An arrhythmia is a problem with the rate or rhythm of the
heartbeat. During an arrhythmia, the heart can beat too fast, too
slow, or with an irregular rhythm. Arrhythmias may not cause any
signs or symptoms. Arrhythmias may be caused by many different
factors, including: Coronary artery disease, Electrolyte imbalances
in Blood, Changes in heart muscle, Injury from a heart attack,
Irregular heart rhythms.
Companies discussed in this Arrhythmias – Pipeline
Review, H1 2015 report include:
- Gilead Sciences, Inc.
- Nyken BV
- Orion Oyj
- SciFluor Life Sciences, LLC
Drugs profiles discussed in this report includes GS-967,
KN-93, NYK-1112, ORM-10103, PP-1, Small Molecule for Arrhythmia,
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart
Failure, Small Molecules to Inhibit Vesicular Acetylcholine
Transporter for Arrhythmias, VKII-86. Order a Purchase copy of
this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=365315 .
(This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or
altered based on the availability and relevance of data for the
indicated disease.
The report enhances decision making capabilities and help to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Global Markets Direct's report features investigational drugs
from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced
from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources, put together by Global
Markets Direct's team. Drug profiles/records featured in the report
undergoes periodic updation following a stringent set of processes
that ensures that all the profiles are updated with the latest set
of information. Additionally, processes including live news &
deals tracking, browser based alert-box and clinical trials
registries tracking ensure that the most recent developments are
captured on a real time basis.
Reasons to buy
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Arrhythmias
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Arrhythmias pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Explore more reports on Cardiovascular therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics
.
More reports on Cardiovascular therapeutics
Pulmonary Arterial Hypertension – Pipeline Review, H1
2015
This report provides comprehensive information on the
therapeutic development for Pulmonary Arterial Hypertension. The
report reviews key players involved in the therapeutics development
for Pulmonary Arterial Hypertension and enlists all their major and
minor projects. Companies discussed in this report include Actelion
Ltd, APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi
Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca,
S.A., Cardioxyl Pharmaceuticals, Inc., Carolus Therapeutics, Inc.,
Celladon Corporation, Celsion Corporation, Corridor Pharmaceuticals
Inc., Cytokinetics, Inc., Eli Lilly and Company, Gilead Sciences,
Inc., HanAll Biopharma Co., Ltd., Insmed Incorporated, Ironwood
Pharmaceuticals, Inc., Lacer, S.A., Longevity Biotech, Inc, LTT
Bio-Pharma Co., Ltd., Mast Therapeutics, Inc., Mezzion Pharma Co.
Ltd., miRagen Therapeutics, Inc., Nippon Shinyaku Co., Ltd.,
Novartis AG, PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc.,
Pluristem Therapeutics Inc., Proteo, Inc., Reata Pharmaceuticals,
Inc., Sagene Pharmaceuticals, Inc., Silence Therapeutics plc,
Sinoxa Pharma GmbH, Suda Ltd, Therametrics holding AG, Toray
Industries, Inc., United Therapeutics Corporation.
Peripheral Artery Occlusive Disease (PAOD) – Pipeline Review,
H1 2015
This report provides comprehensive information on the
therapeutic development for Peripheral Artery Occlusive Disease
(PAOD). The report provides a snapshot of the global therapeutic
landscape of Peripheral Artery Occlusive Disease (PAOD). Companies
discussed in this report include Annexin Pharmaceuticals AB, Apceth
GmbH & Co. KG, AstraZeneca PLC, Athersys, Inc., Bayer AG,
Betagenon AB, Cardiolynx AG, CardioVascular BioTherapeutics, Inc.,
Celgene Corporation, Cytokinetics, Inc., Diffusion Pharmaceuticals
LLC, DNAVEC Corporation, Genovate Biotechnology Co., LTD., Grifols,
S.A., Human Stem Cells Institute, Kowa Company, Ltd., Lacer, S.A.,
Ligand Pharmaceuticals, Inc., LTT Bio-Pharma Co., Ltd., miRagen
Therapeutics, Inc., Multi Gene Vascular Systems Ltd, Nuo
Therapeutics, Inc., Pluristem Therapeutics Inc., Proteon
Therapeutics, Inc., Recardio GmbH, RegenoCELL Therapeutics, Inc.,
Rigel Pharmaceuticals, Inc., Sagene Pharmaceuticals, Inc.,
Stemedica Cell Technologies, Inc., Taisho Toyama Pharmaceutical
Co., Ltd., Theravasc, Inc., vasopharm GmbH, ViroMed Co., Ltd.
About Us:
RnRMarketResearch.com is a database of selected syndicated
market reports for global and China industries including but not limited to
life sciences, information technology & telecommunications,
consumer goods, food and beverages, energy and power, automotive
and transportation, manufacturing and construction, materials and
chemicals, public sector as well as business and financial
services. We provide 24/7 online and offline support to our
customers. Call +1 888 391 5441 with your research requirements or
email the details on sales@rnrmarketresearch.com This e-mail
address is being protected from spambots. You need JavaScript
enabled to view it and we would be happy to help you find the
business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research,
+1888391544, sales@rnrmarketresearch.com
News distributed by PR Newswire iReach:
https://ireach.prnewswire.com
SOURCE RnR Market Research